Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

siponimod

- PMLiVE

New data puts Jakafi on course for blockbuster status

Novartis/Incyte drug meets targets in blood cancer trial

Novartis building

Novartis’ dermatology plans advance with Xolair approval

Green light for use in chronic spontaneous urticaria

- PMLiVE

Novartis to close UK R&D site

Research operations at Horsham expected to end in June

Novartis day

Novartis commits to greater transparency on trials

Will provide anonymised patient-level data but only for new studies

Novartis day

Novartis under fire in Japan over Diovan promotion

Offices raided amid investigation into falsified data

Novartis building

Novartis skin cancer drug clears pivotal trial

Sonidegib achieves significant response in basal cell carcinoma patients

Novartis building

Novartis enters PD-1 race via CoStim acquisition

Expands presence in cancer immunotherapies

EU flag

EU rules ‘deny cancer therapy to children’

Cancer groups demand change to loophole that allows drugs to be excluded from paediatric trials

EU flag

Pharma cited in EU corruption report

EC says healthcare industry among those vulnerable to corrupt business practice

Novartis building

Novartis planning thousands more job cuts, says paper

NZZ am Sonntag claims pharma company plans to transfer roles to India

- PMLiVE

EU gives boost to its network of HTA bodies

EUnetHTA strengthens role in market access in EU

- PMLiVE

Going off-label?

There’s a thin line between the legitimate and fraudulent 'off-label' promotion, as a recent US court case highlights

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links